

# Non–Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers

Ronald J. Scheff, MD<sup>1</sup> Bryan J. Schneider, MD<sup>1</sup>

<sup>1</sup>Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York

Address for correspondence Bryan J. Schneider, MD, Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, 3rd floor, Payson Pavilion, New York, NY 10065 (e-mail: bjs2004@med.cornell.edu).

Semin Intervent Radiol 2013;30:e1

## ERRATUM

The publisher regrets an error with the opening sentence in the above article in *Seminars in Interventional Radiology*, Volume 30, Number 2, 2013. p. 191. The corrected sentence is indicated below.

“Non-small cell lung cancer (NSCLC), the leading cause of cancer-related mortality in the United States, and a leading cause of cancer-related mortality worldwide, remains a formidable clinical challenge.”